Cargando…

Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic cause of Parkinson’s disease. Here, we investigated whether the G2019S LRRK2 mutation causes morphological and/or functional changes at nigro-striatal dopamine neurons. Density of striatal dopaminergic terminals,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Longo, Francesco, Mercatelli, Daniela, Novello, Salvatore, Arcuri, Ludovico, Brugnoli, Alberto, Vincenzi, Fabrizio, Russo, Isabella, Berti, Giulia, Mabrouk, Omar S., Kennedy, Robert T., Shimshek, Derya R., Varani, Katia, Bubacco, Luigi, Greggio, Elisa, Morari, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351259/ https://www.ncbi.nlm.nih.gov/pubmed/28292328 http://dx.doi.org/10.1186/s40478-017-0426-8

Ejemplares similares

Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice
por: Domenicale, Chiara, et al.
Publicado: (2022)

Leucine‐rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes
por: Mercatelli, Daniela, et al.
Publicado: (2019)

Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging
por: Longo, Francesco, et al.
Publicado: (2014)

LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex
por: Cirnaru, Maria D., et al.
Publicado: (2014)

Parkinson’s Disease–Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance
por: Streubel-Gallasch, Linn, et al.
Publicado: (2021)

LRRK2 and neuroinflammation: partners in crime in Parkinson’s disease?
por: Russo, Isabella, et al.
Publicado: (2014)

Parkinson’s disease: no NOP, new hope
por: Arcuri, Ludovico, et al.
Publicado: (2016)

Autophagy and LRRK2 in the Aging Brain
por: Albanese, Federica, et al.
Publicado: (2019)

Revisiting the specificity and ability of phospho-S129 antibodies to capture alpha-synuclein biochemical and pathological diversity
por: Lashuel, Hilal A., et al.
Publicado: (2022)

Role of LRRK2 in the regulation of dopamine receptor trafficking
por: Rassu, Mauro, et al.
Publicado: (2017)

Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4
por: Russo, Isabella, et al.
Publicado: (2018)

Pramipexole Reduces Phosphorylation of α-Synuclein at Serine-129
por: Chau, Kai-Yin, et al.
Publicado: (2013)

α-Synuclein serine129 phosphorylation – the physiology of pathology
por: Ramalingam, Nagendran, et al.
Publicado: (2023)

Phospho-S129 Alpha-Synuclein Is Present in Human Plasma but Not in Cerebrospinal Fluid as Determined by an Ultrasensitive Immunoassay
por: Cariulo, Cristina, et al.
Publicado: (2019)

LRRK2 modulates neuronal vesicles cycle through protein interactions
por: Piccoli, Giovanni, et al.
Publicado: (2015)

Surfactant Secretion in LRRK2 Knock-Out Rats: Changes in Lamellar Body Morphology and Rate of Exocytosis
por: Miklavc, Pika, et al.
Publicado: (2014)

In vivo aggregation of presynaptic alpha-synuclein is not influenced by its phosphorylation at serine-129
por: Weston, Leah J., et al.
Publicado: (2021)

Modeling Parkinson’s disease in LRRK2 rodents
por: Domenicale, Chiara, et al.
Publicado: (2023)

GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2
por: Blanca Ramírez, Marian, et al.
Publicado: (2017)

Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation
por: Lobbestael, E., et al.
Publicado: (2016)

Novel antibodies to phosphorylated α-synuclein serine 129 and NFL serine 473 demonstrate the close molecular homology of these epitopes
por: Rutherford, Nicola J., et al.
Publicado: (2016)

Leucine-Rich Repeat Kinase 2 (Lrrk2)-Sensitive Na(+)/K(+) ATPase Activity in Dendritic Cells
por: Hosseinzadeh, Zohreh, et al.
Publicado: (2017)

Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease?
por: Greggio, Elisa, et al.
Publicado: (2011)

CK1BP Reduces α-Synuclein Oligomerization and Aggregation Independent of Serine 129 Phosphorylation
por: Elsholz, Lea, et al.
Publicado: (2021)

Editorial: LRRK2—Fifteen Years From Cloning to the Clinic
por: Rideout, Hardy, et al.
Publicado: (2022)

Trafficking of the glutamate transporter is impaired in LRRK2-related Parkinson’s disease
por: Iovino, Ludovica, et al.
Publicado: (2022)

Phosphorylation of the aggregate-forming protein alpha-synuclein on serine-129 inhibits its DNA-bending properties
por: Dent, Sydney E., et al.
Publicado: (2021)

Increased Phospho‐AKT in Blood Cells from LRRK2 G2019S Mutation Carriers
por: Garrido, Alicia, et al.
Publicado: (2022)

Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-κB p50 signaling in cultured microglia cells
por: Russo, Isabella, et al.
Publicado: (2015)

Erratum to: Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-κB p50 signaling in cultured microglia cells
por: Russo, Isabella, et al.
Publicado: (2016)

LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson’s Disease, Where Do We Stand?
por: Taymans, Jean-Marc, et al.
Publicado: (2016)

Polo-like kinase 2 inhibition reduces serine-129 phosphorylation of physiological nuclear alpha-synuclein but not of the aggregated alpha-synuclein
por: Elfarrash, Sara, et al.
Publicado: (2021)

Polo-like Kinase 2 (PLK2) Phosphorylates α-Synuclein at Serine 129 in Central Nervous System
por: Inglis, Kelly J., et al.
Publicado: (2009)

Investigating the presence of doubly phosphorylated α‐synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases
por: Fayyad, Muneera, et al.
Publicado: (2020)

Differential Phospho‐Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease
por: Garrido, Alicia, et al.
Publicado: (2022)

Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers
por: Wang, Shijie, et al.
Publicado: (2017)

PAK6 Phosphorylates 14-3-3γ to Regulate Steady State Phosphorylation of LRRK2
por: Civiero, Laura, et al.
Publicado: (2017)

Serine 129 Phosphorylation of α-Synuclein Cross-Links with Tissue Transglutaminase to Form Lewy Body-Like Inclusion Bodies
por: Bi, Wei, et al.
Publicado: (2011)

α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity
por: Ghanem, Simona S., et al.
Publicado: (2022)

Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson's disease kinase
por: Lis, Pawel, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0pm2e3sdl144p81jc90c4pjp1d